tbuckley/cabot-search huggingface dataset:
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
Authors: Lawrence Kleinberg, Jeffrey G. Supko, Tom Mikkelsen, Jaishri O'Neill Blakeley, Glen Stevens, Xiaobu Ye, Serena Desideri, Samuel Ryu, Bhardwaj Desai, Vincent L. Giranda, Stuart A. Grossman
Journal: Journal of Clinical Oncology (2013)

2065 Background: ABTC conducted a dose finding trial of ABT-888, an orally administered Poly(ADP-ribose) polymerase [PARP] inhibitor, during daily TMZ with post-operative RT for GBM. PARP is important in repair pathways for RT induced DNA injury and TMZ induced alkylation at N7-methylguanine and N3-methyldenine. Methods: An initial safety group (no concurrent RT), received ABT-888 10 mg BID po during 42 days of daily TMZ 75 mg/m 2 . After this, the planned dosing steps included ABT-888 BID concurrent with standard RT and TMZ, with planned ABT-888 dose escalation or de-escalation based on observed toxicity. Dose limiting toxicity (DLT) is ≥ grade 3 non-hematologic or neurologic not responding to steroids, and hematologic ANC&lt;500/mm 3 and platelets (PLT) &lt; 25K/mm 3 . The pharmacokinetics (PK) of ABT-888 were characterized for dose 1 and at steady-state. Results: Without concurrent RT, DLT (thrombocytopenia) occurred in 1/6 patients. With concurrent RT/TMZ and ABT-888 10 mg BID, 4/12 patients had DLT (thrombocytopenia). As per the planned dose de-escalation, ABT-888 10 mg BID was then given every other week during TMZ/RT. This resulted in 3/6 patients with DLT (2 thrombocytopenia, 1 neutropenia). The hematologic toxicity with this regimen was judged high enough that accrual was discontinued. In the setting of continuous dosing for 6 weeks, the total body clearance of ABT-888 for the first dose (27.5±9.5 L/h, n = 15) and at steady-state after BID dosing (23.5±10.4 L/h, n = 18) were similar. Accumulation for BID dosing was 56±33%. Steady-state peak and trough concentrations of the drug in plasma were 66±29 ng/mL and 18±10 ng/mL, respectively. Additional PK data will be presented. Conclusions: Administering ABT-888 BID po in combination with standard RT/TMZ was not tolerable in GBM patients as a result of hematologic toxicity. ABT-888 PK in GBM patients were very similar to findings reported for solid tumor patients. There is strong scientific rationale for continued development of an appropriate dosing regimen for this agent in the initial therapy of GBM. Clinical trial information: NCT00770471.
Qol and adherence to i.v. or oral chemotherapy treatment in elderly patients with advanced NSCLC.
Authors: Sebastiano Bordonaro, Alfredo Butera, Francesca Spinnato, Giovanna Antonelli, Vittorio Gebbia, Michele Caruso, Dorotea Sciacca, Paolo Tralongo
Journal: Journal of Clinical Oncology (2012)

e18002 Background: In elderly patients with advanced stage NSCLC the identification of the best treatment-related quality of life becomes the main discriminating endpoint. Methods: In this multicentre study, 53 elderly (≥ 70 yrs) patients with advanced (IIIB-IV) NSCLC were randomly allocated to receive as first-line treatment either Gemcitabine intravenously (1000 mg/m 2 ) or oral Vinorelbine (60 mg/m 2 ) both on days 1 and 8, every 21 days. The primary objective was the evaluation of the QoL, while the secondary one was the assessment of treatment adherence. The EORTC QLQ-C30 v 2.0 and QLQ-LC13 questionnaires have been used to evaluate the quality of life and an “ad hoc” questionnaire for the estimate of adherence/compliance to treatment in patients receiving oral Vinorelbine. The questionnaires were filled in at baseline and every 3 cycles. Results: Forty-one patients (thirty-six males), median age of 75.7 years, have been considered suitable for evaluation. All patients filled in the QoL questionnaires at baseline, 18 of them after three cycles of treatment. Differences of mean score values of items recorded at each assessment were calculated. Referring to QLQ-C30, patients enrolled in the Vinorelbine arm displayed higher mean scores as compared to those of Gemcitabine. There was a gain of 5.6 points as regards Physical Function and 16.9 points for Social Function in the Vinorelbine arm as compared to 3 and 1.6 points in the Gemcitabine arm. A higher improvement of the symptoms Nausea and Vomiting and Sleep Disturbance in the Vinorelbine arm in comparison with Gemcitabine (- 7 vs. + 3.2 and – 21.3 vs. + 7.7, respectively) was also observed. Patients treated with oral Vinorelbine showed improvements of the majority of QLQ-LC13 scores and completed a higher number of cycles as compared to Gemcitabine. Most patients (93.5%) responded positively to the satisfaction questionnaire of oral Vinorelbine. Conclusions: Oral Vinorelbine may provide an advantage in terms of patient preference since, without reducing the effectiveness, is able to maintain an acceptable toxicity profile which results in a gain of the level of quality of life.
MORPHOLOGICAL APPEARANCE AND REPAIR STRATEGIES OF TRICUSPID REGURGITATION IN PATIENTS WITH UNIVENTRICULAR HEART AND A SYSTEMIC RIGHT VENTRICLE
Authors: Masamichi Ono, Melchior Burri, Julie Cleuziou, Jelena Pabst von Ohain, Elisabeth Beran, Martina Strbad, Alfred Hager, Christian Schreiber, Rüdiger Lange
Journal: Journal of the American College of Cardiology (2017)
RATES OF STROKE AND BLEEDING WITH DABIGATRAN 150 AND 110 MG BID IN CLINICAL PRACTICE: THE GLORIA-AF REGISTRY
Authors: Greg Lip, Menno Huisman, Hans-Christoph Diener, Sergio Dubner, Changsheng Ma, Kenneth Rothman, Shihai Lu, Miney Paquette, Lionel Riou França, Dorothee B. Bartels, Christine Teutsch, Jonathan Halperin
Journal: Journal of the American College of Cardiology (2017)
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).
Authors: Vamsidhar Velcheti, Kurt Schalper, Daniel Carvajal, Lieping Chen, Mario Sznol, Scott N. Gettinger, Roy S. Herbst, David Rimm
Journal: Journal of Clinical Oncology (2013)

11075 Background: Programmed cell death ligand-1 (PDL1) is expressed on various human cancers and is a major mechanism for immune evasion. Preliminary evidence suggests that PDL1 expression on cancer cells predicts response to anti-PD-1 therapy. Here we report our findings using automated quantitative immunofluorescence (QIF) to determine the frequency and prognostic value of PDL1 in two independent NSCLC cohorts. Methods: Five antibodies against PDL1 were screened for sensitivity and specificity using PDL1 transfected cells, normal human placenta and tonsil. Only one monoclonal antibody (clone 5H1) met criteria for specificity. This antibody was used to assess two cohorts of NSCLC cases in TMAs. The cohorts represented 204 cases from Yale University and 340 cases from hospitals in Greece. PDL1 protein was measured using QIF analysis using AQUA method. In addition, in-situ PDL1 mRNA levels were measured in the Greek cohort using the RNAscope paired-primer assay with AQUA method. Results: PDL1 protein expression was detected in 25% and 36% of the studied cohorts, respectively. PDL1 positivity was significantly associated with the presence of tumor-infiltrating lymphocytes (TIL) in both series. Patients with PDL1 protein positivity had better outcome in both series (Log Rank: p=0.036 for Yale cohort, p=0.027 for Greek cohort). Multivariate analysis showed that PDL1 expression was associated with better outcome independent of histology, presence of TILs, and stage in the Greek cohort and marginally significant in the Yale cohort. These findings were further validated by the PDL1 in-situ mRNA measurement in the Greek cohort. PDL1 protein and mRNA levels showed a positive non-linear relationship (R 2 =0.14, P&lt;0.001). Positive PDL1 mRNA was found in 53% of patients with NSCLC and was also associated with the presence of TILs and longer overall survival (31 vs. 43 months, p=0.017). Conclusions: Tumor PDL1 protein positivity is detected in 25-30% of NSCLCs and associates with increased TILs and better outcome. Elevated PDL1 mRNA occurs in a higher proportion of NSCLC cases and provides comparable prognostic information. Measurement of in situ PDL1 protein and mRNA could be of more clinical value than either method alone.
Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)
Authors: Roman Galetto, Isabelle Chion-Sotinel, Agnès Gouble, Julianne Smith
Journal: Blood (2015)
NORMAL FINDINGS ON NONINVASIVE CARDIAC ASSESSMENT AND THE PREDICTION OF HEART FAILURE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Stephen Broughton, Wesley O'Neal, Mouaz Al-Mallah, David Bluemke, Susan Heckbert, Joao Lima, Elsayed Soliman
Journal: Journal of the American College of Cardiology (2017)
ETIOLOGY AND PREDICTORS OF 30-DAY UNPLANNED READMISSION RATES AFTER LEFT VENTRICULAR ASSIST DEVICE PLACEMENT
Authors: Shanti Patel, Priti Poojary, Sumeet Pawar, Aparna Saha, Achint Patel, Kinsuk Chauhan, Pratik Mondal, Jignesh Patel, Ashish Correa, Shiv Kumar Agarwal, Arjun Saradna, Ravikaran Patti, Girish Nadkarni, Vijay Shetty
Journal: Journal of the American College of Cardiology (2017)
DISCORDANCES BETWEEN PREDICTED AND ACTUAL RISK OF ADVERSE EVENTS IN OBESE PATIENTS WITH SUSPECTED CARDIAC ISCHEMIA: INSIGHTS FROM THE PROMISE TRIAL (PROSPECTIVE MULTICENTER IMAGING STUDY FOR EVALUATION OF CHEST PAIN)
Authors: Sheldon E. Litwin, Adrian Coles, Neha Pagidipati, Kerry Lee, Patricia Pellikka, Daniel Mark, James Udelson, Lawton Cooper, Jean Claude Tardif, Randy Cohen, Udo Hoffmann, Pamela Douglas
Journal: Journal of the American College of Cardiology (2017)
Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.
Authors: M. Mansour Ceesay, ZiYi Lim, Michelle Kenyon, Aloysius Y.L. Ho, Stephen Devereux, Steve Schey, Aleksandar Mijovic, Antonio Pagliuca, Ghulam J. Mufti
Journal: Blood (2007)
NORMAL DIAMETER OF THE ASCENDING AORTA IN ADULTS: THE IMPACT OF STRICTER CRITERIA ON SELECTION OF SUBJECTS FREE OF DISEASE
Authors: Muhammad Nabeel Syed, Mirza Mujadil Ahmad, Mirza Nubair Ahmad, Sharmeen Hussaini, Mustafa Noor Muhammad, Syed Haris A. Pir, Bijoy K. Khandheria, A. Jamil Tajik, Khawaja Afzal Ammar
Journal: Journal of the American College of Cardiology (2017)
BLOOD PRESSURE RESPONSE TO CATHETER-BASED RENAL SYMPATHETIC DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION: DATA FROM A NATIONAL MULTICENTER 1-YEAR-FOLLOW-UP STUDY
Authors: Konstantinos P. Tsioufis, Antonios Ziakas, Kyriakos Dimitriadis, P. Davlouros, Maria Marketou, Alexandros Kasiakogias, Athanasios Kordalis, Lefki Nikolopoulou, Costas Thomopoulos, D. Petroglou, Dimitris Tsiachris, Michail Doumas, Charalampos Karvounis, Dimitrios Alexopoulos, Panagiotis Vardas, Ioannis Kallikazaros, Christodoulos I. Stefanadis, Vasilios Papademetriou, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
CONCENTRIC LEFT VENTRICULAR REMODELING IS ASSOCIATED WITH LOW-FLOW SEVERE AORTIC STENOSIS AND LESS REVERSE REMODELING AFTER TAVR: A PARTNER 2 TRIAL ANALYSIS
Authors: Zachary Gertz, Philippe Pibarot, Robert Hodson, Rebecca Hahn, Neil Weissman, Pamela Douglas, Sammy Elmariah, Brian Lindman, Marie-Annick Clavel, Stamatios Lerakis, Amr Abbas, Vinod Thourani, Susheel Kodali, Samir Kapadia, Rakesh Suri, Raj Makkar, Michael Mack, Martin Leon, Howard Herrmann
Journal: Journal of the American College of Cardiology (2017)
CD90 MARKS A POPULATION OF ADVENTITIAL MESENCHYMAL STEM CELLS IN THE HUMAN AORTA THAT EXHIBIT DIMINISHED ANGIOGENIC POTENTIAL IN PATIENTS WITH ASCENDING AORTIC ANEURYSMS
Authors: Katherine Michelis, Aya Kitabayashi, Laura Lecce, Maria Paola Santini, Valentina D'Escamard, Oscar Franzén, Johan L.M. Björkegren, Valentin Fuster, Ramachandra Reddy, Joanna Chikwe, Paul Stelzer, Farzan Filsoufi, Allan Stewart, Ani Anyanwu, Jason Kovacic
Journal: Journal of the American College of Cardiology (2017)
Rituximab Plus Gemcitabine, Ifosfamide, Oxaliplatin (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Hodgkin Lymphoma
Authors: Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Cristina Becchimanzi, Giampaolo Marcacci, Ferdinando Frigeri, Filippo Russo, Antonio Pinto
Journal: Blood (2008)
Clinical Outcome of Stem Cell Transplantation(SCT) in Patients with T Cell Prolymphocytic Leukaemia(T-PLL) Previously Treated with Alemtuzumab: A Multicentre Experience.
Authors: Biju Krishnan, John Swansbury, Bruno Cazin, Robin Ireland, Nicolas Ketterer, Anil Lakhani, Antonio Parreira, Saad Rassam, Daniel Catovsky, Estella Matutes, Claire Dearden
Journal: Blood (2005)
CARDIOVASCULAR MAGNETIC RESONANCE IN THE EVALUATION OF FIBROFATTY INFILTRATION FOR ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY (ARVD/C)
Authors: Andrew D. Choi, Andrew Bradley, Sujata Shanbhag, Peter Kellman, Oscar Levine, Christine Mancini, Marcus Chen, Andrew Arai, W. Patricia Bandettini
Journal: Journal of the American College of Cardiology (2017)
Patients (p) with advanced melanoma receiving rescue surgery (RS), BRAF inhibitors (BRAFi), immunotherapy (IT) or chemotherapy (CT) in an off-protocol, routine clinical setting.
Authors: Jose Luis Cuadra-Urteaga, Jose Luis Manzano, Laura Layos, Cristina Buges, Maria Teresa Fernandez-Figueras, Anna Martinez-Cardus, Alberto Indacochea, Sara Ahlal, Laia Vila, Maria de los Llanos Gil, Aram Boada, Carolina Sanz, Ana Munoz, Vicente Ruiz Porras, Sara Bystrup, Eva Martinez-Balibrea
Journal: Journal of Clinical Oncology (2014)

e20046 Background: The treatment of advanced melanoma has evolved over the last three years to include novel treatments in addition to CT. However, the real value of these different therapies has yet to be examined in off-protocol routine clinical practice. Methods: We have retrospectively analyzed p with advanced melanoma treated in a single institution in an off-protocol routine clinical setting with CT, IT, BRAFi, RS, or imatinib (IM). Clinical factors, type of treatment and mutation status were correlated with progression-free survival (PFS) and overall survival (OS). Results: 68 p were included in the analysis. Median age, 61.4 years; 60.3% males. Predominant tumor sites: extremities (30.9%) or trunk (27.9%). Stage: 8.2% IIIA, 21.3% IIIB, 18% IIIC. 32.4% of p had BRAF mutations, 2.9% had cKIT mutations, and 14.7% had NRAS mutations. 74.2% had primary surgery without lymphadenectomy, 20.6% adjuvant IFN, 16.2% adjuvant radiotherapy. Adjuvant treatment was CT in 44.4% (28 p), BRAFi in 28.6% (18 p), IM in 15.6% (10 p), RS in 25% (17 p), IM in 4.8% (3 p). PFS post-primary surgery was 21 months (m) and was related to stage (P=0.039), Clark (P=0.029) and Breslow (P=0.008), but not to type of adjuvant treatment or mutation status. PFS by type of treatment: 2 m for IT, 6 m for BRAFi, 2 m for CT and 4 m for IM. PFS post-RS was 12 m and was related to the relapse-free interval post-primary surgery, with a cutoff point of 24 m (P=0.002). OS was 35.5 m and was related to age (P=0.022), BRAF mutations (P=0.028), NRAS mutations (P=0.004), Clark (P=0.014), Breslow (P=0.507), stage (P<0.00001), relapse-free interval post-primary surgery (P=0.005) and unresectable recurrence (P=0.019). OS after unresectable metastasis was 9.5 m. OS by type of treatment: 5 m for IT, 10 m for BRAFi, 7 m for CT, and 9 m for IM. Conclusions: This study highlights the benefit achieved with RS in selected p with advanced melanoma. Outcomes to systemic treatments were similar to those previously reported in the literature. In the routine clinical setting, BRAF and NRAS mutations emerged as potential markers of worse prognosis. Complete data will be presented.
Implication of clinical and paraclinical covariates in the pharmacokinetics of high dose MTX (HD-MTX) in patients with osteosarcoma
Authors: C. Dupuis, C. Mercier, S. Salas, C. Yang, J. Deville, M. Balti, J. Ciccolini, A. Iliadis, M. Baciuchka, F. Duffaud, R. Favre
Journal: Journal of Clinical Oncology (2006)

12022 Background: Methotrexate (MTX) is a mainstay in the treatment of ostosarcoma. MTX is characterized by a narrow therapeutic window, combined with high intra- and inter-patient variabilities. In our institute, safe administration of high dose MTX is ensured by using bayesian, adaptive dosing with feedback strategy. In patients with osteosarcoma, up to 20g/patient MTX is administred following an 8h infusion. From the 6th hour, the dose is tailored according to individual pharmacokinetics parameters, determined in real-time from two early sampling times (T3.5, T4.5) and a reference population. This method enables accurate adjustment of most patients around a target Cend of 10 −3 M/L. Still, 15–20% of the patients show reduced MTX elimination rate, thus leading to an overlasting hospitalization time with folate rescue required to prevent severe toxicities. In this work, we studied the relevance of clinical or pareaclinical covariates likely to be associated with the MTX clearance so as to identify patients at risk of impaired elimination with subsequent increase in iatrogeny. Methods: This retrospective study was performed on 49 patients treated with HD-MTX. Population PK parameters were computed using Apis and NonMem routines. The second objective was to predict for how long MTX plasma concentration would remain above 0.2 μM/L, the threshold associated with toxicity, upper which folinic acid is required. Finally, simplified sampling strategy for folate rescue protocol was developed. Results: two covariates (creatinemia and ALAT) have been identified as being correlated with MTX clearance. Besides, simulation of the 0.2μM/L threshold reaching showed that it was possible to predict accurately the time most patients can leave the hospital safely. This, would have led to reduce the hospitalization stay by at least one day in 25% of the patients, thus optimizing their life quality while being cost-effective. Conclusions: in this study, we showed that high dose MTX can be administred safely using an adaptive dosing with drug monitoring strategy. Besides, modelling of MTX PK parameters leads to an accurate estimation of the elimination pattern of this drug, thus enabling a planification of the time patients leave the hospital. No significant financial relationships to disclose.
Crossover in oncology clinical trials.
Authors: Jose Diaz, Cora N. Sternberg, Faisal Mehmud, Thomas E. Delea, Nicholas Latimer, Arundathy N. Bartlett-Pandite, Robert Motzer
Journal: Journal of Clinical Oncology (2015)

e15592 Background: There is an ethical need in oncology trials to allow crossover, defined as patients switching from control to experimental treatment. Crossover makes it difficult to detect and attribute improvements in overall survival (OS) associated with experimental treatment in many studies. There are statistical approaches to correct for confounding of OS data due to crossover. In this case study, OS estimates in the treatment-naive population of the phase III VEG105192 study of pazopanib (PAZ) vs placebo (PBO) in advanced renal cell carcinoma (aRCC) were used to explore the correction of OS for crossover using these approaches. Methods: Indirect comparison of OS for PAZ vs sunitinib (SUN) was conducted in 2010 using the rank preserving structural failure time (RPSFT) analysis of OS from VEG105192, the A6181034 trial of SUN vs interferon (IFN)-α, and pooled results of 4 controlled trials of IFN-α identified in a Cochrane review of immunotherapies for aRCC. OS estimates from these analyses were compared in 2014 with final OS data from COMPARZ, a large randomized controlled trial of PAZ vs SUN that was not confounded by crossover. Results: The intent to treat (ITT) PAZ vs PBO hazard ratio (HR) for OS in VEG105192 was 1.01 (95% CI 0.72-1.42). This analysis was heavily confounded by crossover of PBO patients to PAZ (51%). Post hoc statistical adjustment using RPSFT indicated that PAZ was associated with an OS benefit vs PBO (HR 0.50). This value was used in the base case for the indirect comparison between PAZ and SUN, resulting in an OS HR of 0.97 (95% CI 0.36-2.61). This HR was subsequently confirmed by COMPARZ with an OS HR of 0.92 for PAZ vs SUN (Table). Conclusions: Our case study supports the need to adjust for confounding of OS due to crossover. This enables trials to meet their ethical requirements and provides decision makers a more accurate estimate of treatment benefit. Funding: GlaxoSmithKline
The ENABLE III randomized controlled trial of concurrent palliative oncology care.
Authors: Marie Bakitas, Tor Tosteson, Zhigang Li, Kathleen Lyons, Jay Hull, Zhongze Li, J Nicholas Dionne-Odom, Jennifer Frost, Mark Hegel, Andres Azuero, Tim Ahles, James R. Rigas, J. Marc Pipas, Konstantin H. Dragnev
Journal: Journal of Clinical Oncology (2014)

9512 Background: Evidence from randomized controlled trials (RCTs) supports integration of oncology and palliative care; how soon after diagnosis to initiate palliative care has not been defined. Methods: We conducted a ‘fast track’ RCT of patients with advanced cancer in a rural, NCI-designated cancer center, VAMC, and community clinics in NH and VT to determine the effect of immediate vs. delayed (3 months after diagnosis) entry patients into the ENABLE concurrent oncology palliative care intervention on primary outcome measures: QOL (FACIT-pal), symptom impact (Symptom impact subscale of the QUAL-E, mood (CES-D), at 3 and 6 months and survival at 1 year (from enrollment to death or study completion). Other outcomes included: resource use (hospital and ICU days and ER visits-measured by chart review), and quality of EOL care. Results: Participants (immediate n=104; delayed=103) were mean age 65; 52% male; 65% married; 96% white; 42% lung; 46% newly diagnosed with advanced disease; 17% with brain metastases. The estimated treatment effects (TE) using a terminal decline model (Cohen’s d; immediate minus delayed) for patients from randomization to 3 months were: (mean [SE]: .13 (21.39) for QOL (P=.34), -.21 (3.63) for symptom impact (P=.09), and .04 (3.91) for depressed mood (P=.33). 104 participants died (immediate n=49; delayed n=55) during the study. Compared to delayed entry patients, the risk of death (hazard ratio [HR] (95% CI)) was lower for immediate participants at 1 year 0.72 (95% CI, 0.57-0.89) (P=0.003). Median survival for immediate entry patients was 18.3 months (95% CI, 13.2, 28.0) and 11.8 months (95% CI, 9.0, 24.1) for delayed entry patients (P=0.17). Overall median hospital days (3), ICU days (0), and ER visits (1) were identical. 55% (27) of 49 deaths in immediate and 49% (27) of delayed deaths occurred at home. Conclusions: Immediate vs delayed entry patients experienced a significant survival advantage at 1 year; however longitudinal TE were not statistically different. Future research is needed to define mechanisms of survival advantage in palliative care trials. Clinical trial information: NCT01245621.
COMPARATIVE ASSESSMENT OF SUBINTIMAL VERSUS INTRALUMINAL CROSSING OF INFRAINGUINAL CHRONIC TOTAL OCCLUSION LESIONS
Authors: Ananya Kondapalli, Haekyung Jeon-Slaughter, Ehrin Armstrong, Nicolas Shammas, Andrew Shammas, Anand Prasad, Ian Cawich, Gerardo Rodriguez, Mazen Abu-Fadel, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2017)
SB 9200, a Novel Agonist of Innate Immunity, Shows Potent Antiviral Activity against Resistant HCV Variants
Authors: M. Jones, M. Cunningham, P. Wing, S. DeSilva, A. Sheri, S. Padmanabhan, R. Iyer, N. Afdhal, G. Foster
Journal: Journal of Hepatology (2016)